GT201000107A - Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado. - Google Patents

Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.

Info

Publication number
GT201000107A
GT201000107A GT201000107A GT201000107A GT201000107A GT 201000107 A GT201000107 A GT 201000107A GT 201000107 A GT201000107 A GT 201000107A GT 201000107 A GT201000107 A GT 201000107A GT 201000107 A GT201000107 A GT 201000107A
Authority
GT
Guatemala
Prior art keywords
inhaled
inhibitor
corticoesteroid
pde
compositions including
Prior art date
Application number
GT201000107A
Other languages
English (en)
Spanish (es)
Inventor
Thibert Roch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000107A publication Critical patent/GT201000107A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT201000107A 2007-10-25 2010-04-19 Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado. GT201000107A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32707P 2007-10-25 2007-10-25

Publications (1)

Publication Number Publication Date
GT201000107A true GT201000107A (es) 2012-03-13

Family

ID=40579006

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000107A GT201000107A (es) 2007-10-25 2010-04-19 Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.

Country Status (19)

Country Link
US (1) US20100210611A1 (enExample)
EP (1) EP2211863A4 (enExample)
JP (1) JP2011500731A (enExample)
KR (1) KR20100072295A (enExample)
CN (1) CN101909626A (enExample)
AU (1) AU2008316283A1 (enExample)
CA (1) CA2701956A1 (enExample)
CO (1) CO6270213A2 (enExample)
CR (1) CR11439A (enExample)
DO (1) DOP2010000122A (enExample)
GT (1) GT201000107A (enExample)
IL (1) IL205182A0 (enExample)
MA (1) MA33705B1 (enExample)
MX (1) MX2010004529A (enExample)
NI (1) NI201000069A (enExample)
NZ (1) NZ584876A (enExample)
RU (1) RU2470639C2 (enExample)
WO (1) WO2009052624A1 (enExample)
ZA (1) ZA201002562B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168907A1 (en) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising revamilast and montelukast or zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
JP2017503814A (ja) 2014-01-22 2017-02-02 タケダ ゲー・エム・ベー・ハーTakeda GmbH 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のpde4インヒビターを用いた(およびロイコトリエン調節薬と組み合わせて用いた)治療
CN108267531B (zh) * 2016-12-31 2022-01-11 天津金耀集团有限公司 一种环索奈德有关物质hplc测定方法
IT201900014178A1 (it) * 2019-08-06 2021-02-06 Genetic S P A Esteri del montelukast e loro formulazioni farmaceutiche

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US20040214805A1 (en) * 1999-11-02 2004-10-28 Smithkline Beecham Corporation Method and compositions for treating pulmonary diseases
CA2427814C (en) * 2000-11-07 2009-06-02 Merck & Co., Inc. A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
WO2003024488A2 (en) * 2001-09-19 2003-03-27 Altana Pharma Ag Combination of a pde inhibitor and a leukotriene receptor antagonist
DE10237739A1 (de) * 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2452691T5 (es) * 2003-09-16 2022-09-14 Covis Pharma Gmbh Uso de ciclesonida para el tratamiento de enfermedades respiratorias
AU2004283832B2 (en) * 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
EA200701987A1 (ru) * 2005-03-16 2008-02-28 Элан Фарма Интернэшнл Лтд. Составы из нанодисперсного антагониста лейкотриеновых рецепторов/кортикостероида
WO2007036029A1 (en) * 2005-09-28 2007-04-05 Merck Frosst Canada Ltd. Aerosol powder formulation comprising sieved lactose

Also Published As

Publication number Publication date
JP2011500731A (ja) 2011-01-06
EP2211863A4 (en) 2012-07-25
CA2701956A1 (en) 2009-04-30
RU2010120806A (ru) 2011-11-27
NZ584876A (en) 2012-06-29
MA33705B1 (fr) 2012-11-01
US20100210611A1 (en) 2010-08-19
ZA201002562B (en) 2011-06-29
RU2470639C2 (ru) 2012-12-27
CN101909626A (zh) 2010-12-08
IL205182A0 (en) 2010-11-30
AU2008316283A1 (en) 2009-04-30
WO2009052624A1 (en) 2009-04-30
WO2009052624A9 (en) 2010-11-25
DOP2010000122A (es) 2010-07-15
EP2211863A1 (en) 2010-08-04
CO6270213A2 (es) 2011-04-20
CR11439A (es) 2010-06-21
NI201000069A (es) 2010-08-23
KR20100072295A (ko) 2010-06-30
MX2010004529A (es) 2010-05-10

Similar Documents

Publication Publication Date Title
CY2021012I1 (el) Συνθεσεις για αναπνευστικη απελευθερωση ενεργων παραγοντων και συσχετιζομενες μεθοδοι και συστηματα
BR112015029970A2 (pt) inibidores de cinase
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
UA111343C2 (uk) Фармацевтична композиція, що містить мометазону фуроат та азеластину гідрохлорид, для назального введення
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
BR112014030655A2 (pt) inibidores de pirimidinil tirosina quinase
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
MA35616B1 (fr) Compositions pesticides et procédés associés
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
BR112013020650A2 (pt) dispositivo de resseção artroscópica
WO2007142755A3 (en) Purine analogs
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112014031372A2 (pt) implantes/procedimentos relacionados ao avanço da tuberosidade tibial
BR112014010633A2 (pt) sistema de controle de odor, dispositivo de disseminação programável e cartucho de controle de odor personalizável
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
GT201000107A (es) Composiciones de inhalación que comprenden ácido montelukast y un inhibidor de pde-4 o un corticoesteroide inhalado.
WO2012061789A3 (en) Tetrameric alpha-synuclein and use thereof
MX2014006136A (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
CO6710916A2 (es) Inhibidores de notum pectinacetilesterasa y métodos de su uso
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
WO2013155047A3 (en) Compounds and methods for inhibiting cif virulence factor
NZ708821A (en) Lfa-1 inhibitor formulations
WO2013190497A3 (en) Compositions and methods for treatment of inflammatory diseases of the lung
CR20130520A (es) Composición herbicida que comprende flazasulfuron y metribuzina
EA201200855A1 (ru) Модуляторы crth2